Asset Details
Do you wish to reserve the book?
AACR Annual Meeting 2021
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
AACR Annual Meeting 2021
Do you wish to request the book?
AACR Annual Meeting 2021
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
AACR Annual Meeting 2021
2021
Overview
The results showed a significant improvement in the pathological complete response (co-primary endpoint) in patients with resectable NSCLC treated with neoadjuvant nivolumab (360 mg; n=179) plus platinum-doublet chemotherapy every 3 weeks (24·0%) versus chemotherapy alone (n=179; 2·2%; odds ratio 13·94, 99% CI 3·49–55·75; p<0·0001). Lipika Goyal (Massachusetts General Hospital Cancer Center, Boston, MA, USA) showed that this study met the primary endpoint with an objective response rate of 41·7% (43/103; 95% CI 32·1–51·9) for patients with intrahepatic cholangiocarcinoma with FGFR2 fusions or rearrangements. Dabrafenib plus trametinib in high and low grade glioma Vivek Subbiah (MD Anderson Cancer Center, Houston, TX, USA) presented the results from a non-randomised, open-label, phase 2 study of oral dabrafenib (150 mg twice daily) plus oral trametinib (2 mg once daily) in adult patients with BRAFV600E mutation-positive high-grade or low-grade glioma.
Publisher
Elsevier Ltd,Elsevier Limited
